L'Oréal S.A. (ENXTPA:OR) agreed to acquire an unknown majority stake in Medik8 Limited from Inflexion Private Equity Partners LLP for an estimated enterprise value of ?1 billion on June 9, 2025. The enterprise value of ?1 billion was reported by Reuters. As part of the transaction, Inflexion, a leading European mid-market private equity firm, will remain a minority shareholder. The Founder will continue to serve on the board, with the current management committee also remaining in place to ensure continuity. This acquisition further strengthens L?Oréal?s Luxe portfolio, adding a premium science-backed skincare brand with a proven track record of success, with strong potential for global growth. L?Oréal will start consolidating Medik8 sales from the date of the closing of the transaction. As part of the agreement, L?Oréal has also secured rights to buyout in full the minority shareholders. The transaction is expected to be completed in the next few months after regulatory approvals and other customary conditions.

Matthew Appleton, Aoife McDermott, Asfia Mohsin, Mahesh Varia, Lydia Challen, Guillaume Valois, Thomas Masterman, Elaine Johnston of A&O Shearman advises L'Oréal. J.P. Morgan Securities plc acted as financial advisor to Medik8 Limited. BofA Securities Europe SA acted as financial advisor to L'Oréal S.A. (ENXTPA:OR).Jonny Bethell, James Goold, Ed Waldron, Suzy Davis, Alexandra Poland, Liz Wilson, Bridget Winters, Louisa Penny, Martin Yells, Sean Nesbitt, Emma Oakley, Emma Allen, Giles Crown, Sian Skelton, Anneka Dalton and Simon Jupp of Taylor Wessing acted as legal advisor for Medik8 Limited and Inflexion Private Equity Partners LLP. Tim Hewens, Alex Critchley and Linda Zeman of Simmons & Simmons LLP acted as legal advisor for the management of Medik8 Limited.